COMMUNIQUÉS West-GlobeNewswire
-
Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update
10/08/2026 -
Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review
10/08/2026 -
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
10/08/2026 -
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
10/08/2026 -
Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
10/08/2026 -
Instinct Bio Announces Strategic Collaboration with PT PARVA CANDELA to Develop Cosmetics Business in Indonesia
10/08/2026 -
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
10/08/2026 -
ChemoMetec enters collaboration agreement with Roche Diagnostics
10/08/2026 -
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
10/08/2026 -
Internationally Recognized Johns Hopkins Oncologist Dr. Stephen J. Noga Joins Immunocine as Chief Medical Officer
10/08/2026 -
Reacta Healthcare Announces the Appointment of Iedena Lima as Head of Research and Development
10/08/2026 -
Zelluna ASA: New share capital registered
10/08/2026 -
From a Simple Idea to Thousands of Smiles: Teddy Bears On Call Celebrates 10 Years of Comforting Children in Crisis Through Its 3rd Annual Charity Golf Tournament
10/08/2026 -
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
10/08/2026 -
Novonesis to acquire remaining share of MicroBioGen to strengthen yeast capabilities
10/08/2026 -
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
10/08/2026 -
AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million
10/08/2026 -
AB Science annonce aujourd’hui le succès d’augmentations de capital d’un montant brut total de 14,2 millions d’euros
10/08/2026 -
Kylo Peptides Expands Research Catalog to 36 Compounds as Peptide Science Enters a Record Growth Cycle
10/08/2026
Pages